PharmaCyte Biotech, Inc. filings document the company's public-company reporting, capital structure and governance as a Nasdaq-listed biotechnology issuer with common stock registered under PMCB. Recent disclosures include 8-K material-event reports, proxy statements for stockholder votes, equity incentive plan amendments, securities issuance authorizations, preferred stock and warrant financing terms, and notices related to periodic reporting.
The filings also document material agreements tied to external investments and capital deployment, alongside shareholder voting mechanics and security-structure disclosures for common stock, convertible preferred stock and warrants.
PharmaCyte Biotech, Inc. director Michael M. Abecassis received a grant of stock options covering 119,170 shares of common stock. The options have an exercise price of $0.67 per share and expire on March 30, 2036. According to the terms, the options vest in full on the date of the company’s next annual meeting of stockholders, subject to his continued service.
PharmaCyte Biotech, Inc. reported results of its annual stockholder meeting held by webcast. Stockholders approved all five proposals, including an amendment to the 2022 Equity Incentive Plan that increases the shares of common stock available for awards by 2,000,000.
Five directors were elected to serve until the next annual meeting, each receiving over 3.3 million votes in favor, with broker non-votes recorded. Stockholders also ratified CBIZ CPAs P.C. as independent auditor for the fiscal year ending April 30, 2026.
Investors approved, on a non-binding advisory basis, the compensation of the named executive officers. They further authorized the board, but did not require it, to implement a reverse stock split of the outstanding common stock at any ratio between 1-for-1.1 and 1-for-100.
PharmaCyte Biotech, Inc., identified as a ten percent owner of FEMASYS INC, filed a Form 4 related to FEMASYS common stock. The provided data show no reported purchases, sales, or derivative exercises, with all transaction counters and share amounts recorded as zero.
PharmaCyte Biotech reported financial results for the three and nine months ended January 31, 2026, as it continues developing its Cell-in-a-Box-based cancer therapies while its pancreatic cancer program remains on FDA clinical hold. The company generated no revenue, reflecting its development-stage status.
For the quarter, PharmaCyte recorded net income of $746,860, driven mainly by fair value gains on investments and warrant-related items, but a net loss attributable to common stockholders of $1.56 million, or $0.17 per share, after preferred stock accretion and dividends. For the nine months, the loss attributable to common stockholders was $18.33 million, or $2.41 per share.
As of January 31, 2026, the company held $20.2 million in cash and cash equivalents and total assets of $55.9 million, including sizable fair value investments in Femasys and Q/C Technologies preferred shares and warrants. Stockholders’ equity declined to $38.1 million, while warrant and derivative liabilities increased to $14.8 million, reflecting the liability classification of these instruments.
Operating cash outflow for the nine months was $3.76 million, partly offset by $2.0 million of net investing inflows and $6.75 million of financing inflows from the August 2025 Series C convertible preferred stock and warrant financing and warrant exercises. Management states that current cash is expected to fund projected operating requirements for at least twelve months, but additional capital will be needed to complete a pancreatic cancer clinical trial and broader development plans, and equity or debt financing could be dilutive or restrictive.
PharmaCyte Biotech, Inc. is holding a virtual annual stockholder meeting on March 30, 2026 to vote on key corporate matters. Stockholders will elect five directors, ratify CBIZ CPAs P.C. as independent auditor, and cast an advisory vote on executive compensation.
They will also vote on a reverse stock split of common stock at a ratio between 1‑for‑1.1 and 1‑for‑100, and on amending the 2022 Equity Incentive Plan to increase shares available for awards by 2,000,000. The board recommends approval of all proposals.
PharmaCyte Biotech, Inc. is soliciting proxies for a virtual annual meeting at 11:00 a.m. ET on March 30, 2026. The board seeks stockholder votes to elect five directors; ratify CBIZ CPAs P.C. as auditor; approve advisory executive compensation; approve a reverse stock split at a ratio between 1-for-1.1 and 1-for-100 (exact ratio to be set by the board); and approve an amendment to the 2022 Equity Incentive Plan to add 2,000,000 shares for awards. The record date and voting power rules: holders of common stock and Series C Preferred Stock as of January 30, 2026 may vote. Shares outstanding on the Record Date were 10,735,649, and Series C Preferred Stock converts to 2,677,093 votes on an as-converted basis. Several related-party investments and transactions are disclosed, and the board recommends approval of each proposal.
PharmaCyte Biotech, Inc. investors update their ownership report. As of the close of business on December 31, 2025, Mitchell P. Kopin and Intracoastal Capital LLC each report beneficial ownership of 532,254 shares of common stock, or about 4.99% of the class. Daniel B. Asher reports beneficial ownership of 531,086 shares, also about 4.99%.
Their positions are mainly through warrants and preferred stock held by Intracoastal. Multiple warrants and Series H Convertible Preferred Stock include 4.99% blocker provisions, which limit conversions or exercises that would push their beneficial ownership above that threshold. The percentages are calculated using 10,134,160 shares outstanding as of December 16, 2025 plus specified warrant shares.
The reporting persons certify the securities are not held for the purpose of changing or influencing control of PharmaCyte, and the filing reflects that they each own 5 percent or less of the common stock class.
PharmaCyte Biotech, Inc. CEO and President Joshua Silverman reported multiple open-market purchases of the company’s common stock. On January 5, 2026, he bought 30,000 shares at $0.7831 per share. On January 6, 2026, he bought another 30,000 shares at $0.7889 per share, and on January 7, 2026, he bought 40,000 shares at $0.8329 per share.
After these transactions, Silverman directly beneficially owned 416,250 shares of PharmaCyte common stock and indirectly beneficially owned an additional 50,000 shares through JNS Holdings Group LLC.
PharmaCyte Biotech director buys additional shares
Director Jonathan Schechter reported buying a total of 60,000 shares of PharmaCyte Biotech, Inc. common stock in the open market over three consecutive days. He purchased 20,000 shares on January 5, 2026 at $0.7776 per share, 20,000 shares on January 6, 2026 at $0.7904 per share, and 20,000 shares on January 7, 2026 at $0.8436 per share. Following these transactions, Schechter directly owned 192,500 shares of PharmaCyte common stock.